Grant of Options under Long Term Incentive Scheme

AI SummaryClose X

Allergy Therapeutics plc announced on January 28, 2026, that it granted share option awards to key management personnel, including persons discharging managerial responsibilities, on January 27, 2026. These options are designed to incentivize long-term value creation and align management interests with stakeholders, with 70% vesting based on Adjusted EBITDA performance and 30% on share price performance over a three-year period. The Chief Executive Officer received 5,409,724 options, and the Chief Financial Officer received 2,489,627 options, both with an exercise price of £0.001. Following these grants, the company has options outstanding over 365,205,852 ordinary shares, representing 5.95% of its current issued share capital.

Disclaimer*

UK 100

Latest directors dealings